Expect Deals To Increase In 2015, But Value To Diminish, Analyst Says
This article was originally published in The Pink Sheet Daily
Panelists at the BIO CEO conference in New York City discussed the deal trends that shaped 2014, and what the biopharma industry can expect to see this year.
You may also be interested in...
The year 2014 was the biggest for pharma M&A in recent history, though it may be remembered equally for sagas and upsets that never materialized into finalized deals. Actavis, in the end, was the most aggressive acquirer, buying Forest and Allergan for a total of $89.3 billion in the two most expensive deals of the year.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.